While the broader stock market suffered steep losses on Friday amid trade policy shifts and troubling economic data, select health technology equities stood out.
Notably, 4D Molecular Therapeutics (NASDAQ: FDMT), Sensei Biotherapeutics (NASDAQ: SNSE), and Alphatec Holdings (NASDAQ: ATEC) posted massive single-day gains, averaging about 37%. The rallies were largely fueled by clinical updates, investor sentiment, and raised guidance.
4D Molecular Therapeutics (NASDAQ: FDMT)
Shares of 4D Molecular Therapeutics surged over 42% to close at $6.42 after the company released promising new clinical data for its gene therapy candidate, 4D-150, targeting diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD).
The therapy demonstrated strong, dose-dependent results. At the Phase 3 dose, patients reportedly experienced a 78% reduction in treatment burden compared to standard aflibercept dosing. Visual improvements and anatomical gains were sustained, and the treatment remained well tolerated, with no inflammation reported.
In a further boost, the European Medicines Agency endorsed the company’s plan to seek approval based on a single Phase 3 trial, echoing earlier alignment with the FDA.
Sensei Biotherapeutics (NASDAQ: SNSE)
Sensei Biotherapeutics emerged as one of the day’s top gainers despite no major company-specific news. The surge may reflect increased speculative interest in its immuno-oncology pipeline or anticipation of trial data.
The rally followed recent news that Sensei will present clinical data from its Phase 1/2 trial of its lead candidate, solnerstotug, both as a monotherapy and in combination with Regeneron’s Libtayo, at the European Society for Medical Oncology Congress on October 17 in Berlin.
The update will feature results from the dose expansion cohort, including patients with advanced solid tumors resistant to prior PD-(L)1 treatments.
At the close on August 1, SNSE stock was up 38%, ending the day at $10.32.
Alphatec Holdings (NASDAQ: ATEC)
Alphatec Holdings jumped 30%, closing at $13.77, after the company raised its full-year 2025 revenue outlook to $742 million, citing robust demand for its surgical platforms and EOS imaging technologies.
The spine-focused medical tech company also reported second-quarter 2025 revenue of $185.5 million, a 28% year-over-year increase. However, net loss widened slightly to $41.1 million, or $0.27 per share.
While the company remains unprofitable, investor confidence appears to be growing in Alphatec’s commercial execution and long-term growth prospects.
Featured image via Shutterstock
